Algert Global LLC Kodiak Sciences Inc. Transaction History

Algert Global LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.8 - $7.49 $84,384 - $351,131	-46,880 Reduced 40.54%	68,750 $124,000
Q2 2023 Aug 14, 2023	SELL	$4.3 - $9.48 $449,883 - $991,835	-104,624 Reduced 47.5%	115,630 $798,000
Q1 2023 May 12, 2023	BUY	$4.81 - $8.88 $171,760 - $317,095	35,709 Added 19.35%	220,254 $1.37 Million
Q4 2022 Feb 13, 2023	BUY	$6.52 - $8.05 $369,618 - $456,354	56,690 Added 44.34%	184,545 $1.32 Million
Q3 2022 Nov 15, 2022	BUY	$7.57 - $12.5 $814,115 - $1.34 Million	107,545 Added 529.52%	127,855 $990,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $102,362 - $192,538	20,310 New	20,310 $155,000
Q4 2021 Feb 14, 2022	SELL	$80.85 - $128.49 $170,593 - $271,113	-2,110 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$81.97 - $106.94 $172,956 - $225,643	2,110 New	2,110 $203,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $288M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.